본문 바로가기 주메뉴 바로가기
22대 대한민국 국회 국회정보길라잡이 국회의원검색
회원가입 로그인
HOME

정보검색

소장정보 검색

국회도서관 홈으로 정보검색 소장정보 검색
결과 내 검색 동의어 포함
결과 내 검색 동의어 포함

-

초록보기

Purpose Exon 20 insertion mutations (E20ins) in epidermal growth factor receptor (EGFR) or human epidermal growth factor receptor 2 (HER2) in non–small cell lung cancer (NSCLC) patients has become more important with emergence of novel agents targeting E20ins.

Materials and Methods Advanced/Metastatic NSCLC patients with E20ins were included. EGFR E20ins was identified by two methods, next-generation sequencing (NGS) or real-time polymerase chain reaction (PCR), while HER2 E20ins was done by NGS only.

Results Between December 2013 and July 2021, E20ins were identified in 107 patients at Asan Medical Center; 67 EGFR E20ins and 40 HER2 E20ins. Out of 32 patients with EGFR E20ins who had tested both PCR and NGS, 17 were identified only through NGS and the other 15 through both tests, giving a discordance rate of 53.1%. There was no clinically significant difference in clinicopathologic features between EGFR and HER2 E20ins; both were observed more frequently in adenocarcinoma, female and never-smokers. Brain metastases were evident at diagnosis in 31.8% of EGFR E20ins and 27.5% of HER2 E20ins, respectively. Platinum-based doublets demonstrated objective response rates (ORR) of 13.3% with a median progression-free survival (PFS) of 4.2 months for EGFR E20ins and 35.3% with 4.7 months for HER2 E20ins, respectively. In contrast, novel EGFR E20ins-targeted agents exhibited an ORR of 46.2% with a median PFS of 5.4 months, while HER2-targeted agents showed an ORR of 50% with that of 7.0 months.

Conclusion Identification of EGFR and HER2 E20ins is more important as their targeted therapies improved outcomes. Upfront NGS test as a comprehensive molecular approach is strongly warranted.

권호기사

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 목차
HER2-low breast cancer : now and in the future Sora Kang, Sung-Bae Kim p. 700-720

Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer : a joint report from KSMO and KSP Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo ... [et al.] p. 721-742

Phase 1/2a study of rivoceranib, a selective VEGFR-2 angiogenesis inhibitor, in patients with advanced solid tumors Yoon-Koo Kang, Min-Hee Ryu, Yong Sang Hong, Chang-Min Choi, Tae Won Kim, Baek-Yeol Ryoo, Jeong Eun Kim, John R. Weis, Rachel Kingsford, Cheol Hee Park, Seong Jang, Arlo McGinn, Theresa L. Werner, Sunil Sharma p. 743-750

Association of immune-related adverse events and the efficacy of anti-PD-(L)1 monotherapy in non-small cell lung cancer : adjusting for immortal-time bias Ying Yu, Ning Chen, Sizhe Yu, Wanji Shen, Wanchen Zhai, Hui Li, Yun Fan p. 751-764

Analytical and clinical validation of a highly sensitive NGS-based ctDNA assay with real-world concordance in non-small cell lung cancer Hanbaek Yi, Jeonghwan Youk, Yoojoo Lim, Hanseong Roh, Dongsoo Kyung, Hwang-Phill Kim, Duhee Bang, Bhumsuk Keam, Tae-Min Kim, Miso Kim, Dong-Wan Kim, Tae-You Kim p. 765-773

Comparison of clinicopathogenomic features and treatment outcomes of EGFR and HER2 Exon 20 insertion mutations in non-small cell lung cancer : single-institution experience So Heun Lee, Hyehyun Jeong, Deok Hoon Kim, Se Jin Jang, Sang-We Kim, Shinkyo Yoon, Dae Ho Lee p. 774-784

Contribution of enhanced locoregional control to improved overall survival with consolidative durvalumab after concurrent chemoradiotherapy in locally advanced non-small cell lung cancer : insights from real-world data Jeong Yun Jang, Si Yeol Song, Young Seob Shin, Ha Un Kim, Eun Kyung Choi, Sang-We Kim, Jae Cheol Lee, Dae Ho Lee, Chang-Min Choi, Shinkyo Yoon, Su Ssan Kim p. 785-794

Trastuzumab Biosimilar (HLX02), pertuzumab plus chemotherapy in patients with HER2-positive metastatic breast cancer after progression of trastuzumab : a prospective, phase Ⅱ study Ruyan Zhang, Xiaoran Liu, Guohong Song, Yan Zhang, Huiping Li p. 795-801

Implementation of BRCA test among young breast cancer patients in South Korea : a nationwide cohort study Yung-Huyn Hwang, Tae-Kyung Yoo, Sae Byul Lee, Jisun Kim, Beom Seok Ko, Hee Jeong Kim, Jong Won Lee, Byung Ho Son, Il Yong Chung p. 802-808

(The) clinical efficacy of colorectal cancer patients with pulmonary oligometastases by sterotactic body ablative radiotherapy : a meta-analysis Jae-Uk Jeong, Chai Hong Rim, Gyu Sang Yoo, Won Kyung Cho, Eui Kyu Chie, Yong Chan Ahn, Jong Hoon Lee p. 809-824

(The) persistence of hypertriglyceridemia and the risk of early onset colorectal cancer according to tumor subsites : a nationwide population-based study Young Hoon Chang, Cheol Min Shin, Kyungdo Han, Jin Hyung Jung, Eun Hyo Jin, Joo Hyun Lim, Seung Joo Kang, Yoon Jin Choi, Hyuk Yoon, Young Soo Park, Nayoung Kim, Dong Ho Lee p. 825-837

Combined high-dose radiotherapy with sequential gemcitabine-cisplatin based chemotherapy increase the resectability and survival in locally advanced unresectable intrahepatic cholangiocarcinoma : a multi-institutional cohort study Jung Ho Im, Jeong Il Yu, Tae Hyun Kim, Tae Gyu Kim, Jun Won Kim, Jinsil Seong p. 838-846

Global expanded access program for pemigatinib in patients with previously treated locally advanced or metastatic cholangiocarcinoma and fibroblast growth factor receptor gene alterations Anouk Lindley, Gerald Prager, Michael Bitzer, Timothy C. Burn, Christine F. Lihou, Elisabeth Croft p. 847-855

Invasiveness of upper tract urothelial carcinoma : clinical significance and integrative diagnostic strategy Bokyung Ahn, Doeun Kim, Kye Jin Park, Ja-Min Park, Sun Young Yoon, Bumsik Hong, Yong Mee Cho, Deokhoon Kim p. 856-870

Adjuvant chemotherapy for upper tract urothelial carcinoma : a real-world, retrospective study Junho Lee, Sung Hee Lim, Jae Hoon Chung, Wan Song, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park p. 871-876

Single early intravesical instillation of epirubicin for preventing bladder recurrence after nephroureterectomy in upper urinary tract urothelial carcinoma Jong Hoon Lee, Chung Un Lee, Jae Hoon Chung, Wan Song, Minyong Kang, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Hwan Sung p. 877-884

Bilateral seminal vesicle invasion as a strong prognostic indicator in T3b prostate cancer patients following radical prostatectomy : a comprehensive, multicenter, long-term follow-up study Jungyo Suh, In Gab Jeong, Hwang Gyun Jeon, Chang Wook Jeong, Sangchul Lee, Seong Soo Jeon, Seok-Soo Byun, Cheol Kwak, Hanjong Ahn p. 885-892

Neoadjuvant cisplatin-based chemotherapy followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of the bladder : post hoc analysis of two prospective studies Sung Wook Cho, Sung Hee Lim, Ghee Young Kwon, Chan Kyo Kim, Won Park, Hongryull Pyo, Jae Hoon Chung, Wan Song, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park p. 893-897

Predicted cervical cancer prevention : impact of national HPV vaccination program on young women in South Korea Kyeongmin Kwak, Seung-sik Hwang p. 898-908

(The) role of early and delayed surgery for infants with congenital brain tumors Jong Seok Lee, Ji Yeoun Lee, Kyung Hyun Kim, Sung-Hye Park, Eun Jung Koh, Seung-Ki Kim, Ji Hoon Phi p. 909-919

Feasibility of circulating tumor DNA analysis in patients with follicular lymphoma Sang Eun Yoon, Seung-Ho Shin, Dae Keun Nam, Junhun Cho, Won Seog Kim, Seok Jin Kim p. 920-935

Secondary malignancies in multiple myeloma in Korean patients : a nationwide population-based study Boyoung Park, Eunyoung Lee, Junghyun Yoon, YoungJu Park, Hyeon-Seok Eom p. 936-944

CD19-specific CAR-T cell treatment of 115 children and young adults with acute B lymphoblastic leukemia : long-term follow-up Yu Wang, Yu-juan Xue, Ying-xi Zuo, Yue-ping Jia, Ai-dong Lu, Hui-min Zeng, Le-ping Zhang p. 945-955

Nation-wide retrospective analysis of allogeneic stem cell transplantation in patients with multiple myeloma : a study from Korean Multiple Myeloma Working Party (KMM1913) Ho-Jin Shin, Do-Young Kim, Kihyun Kim, Chang-Ki Min, Je-Jung Lee, Yeung-Chul Mun, Won-Sik Lee, Sung-Nam Lim, Jin Seok Kim, Joon Ho Moon, Da Jung Kim, Soo-Mee Bang, Jong-Ho Won, Jae-Cheol Jo, Young Il Koh p. 956-966

Molecular and treatment characteristics of SMARCB1 or SMARCA4-deficient undifferentiated tumor : retrospective case series Hyeon Gyu Kang, Jiwon Koh, Tae Min Kim, Doo Hee Han, Tae-Bin Won, Dong-Wan Kim, Dong-Young Kim, Bhumsuk Keam p. 967-971

(Correspondence) Bridging the gap between trial adverse events and real-world data Sang Hyuk Kim, Hyun Lee, Dong Won Park p. 972-973

참고문헌 (32건) : 자료제공( 네이버학술정보 )

참고문헌 목록에 대한 테이블로 번호, 참고문헌, 국회도서관 소장유무로 구성되어 있습니다.
번호 참고문헌 국회도서관 소장유무
1 Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239-46. 미소장
2 Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167-77. 미소장
3 Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963-71. 미소장
4 Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, et al. Osimertinib in pretreated T790M-positive advan-ced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol. 2017;35:1288-96. 미소장
5 Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016;17:984-93. 미소장
6 Baraibar I, Mezquita L, Gil-Bazo I, Planchard D. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC. Crit Rev Oncol Hematol. 2020;148:102906. 미소장
7 Beau-Faller M, Prim N, Ruppert AM, Nanni-Metellus I, Lacave R, Lacroix L, et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol. 2014;25:126-31. 미소장
8 Morita C, Yoshida T, Shirasawa M, Masuda K, Matsumoto Y, Shinno Y, et al. Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions. Sci Rep. 2021;11:18762. 미소장
9 Pillai RN, Behera M, Berry LD, Rossi MR, Kris MG, Johnson BE, et al. HER2 mutations in lung adenocarcinomas: a report from the Lung Cancer Mutation Consortium. Cancer. 2017; 123:4099-105. 미소장
10 Le X, Goldman JW, Clarke JM, Tchekmedyian N, Piotrowska Z, Chu D, et al. Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients. J Clin Oncol. 2020;38(15 Suppl):9514. 미소장
11 Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol. 2021;39:3391-402. 미소장
12 Zhou C, Ramalingam SS, Kim TM, Kim SW, Yang JC, Riely GJ, et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial. JAMA Oncol. 2021;7: e214761. 미소장
13 Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazieres J, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2022;386:241-51. 미소장
14 Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, Butaney M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013;8:179-84. 미소장
15 Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012;18:4910-8. 미소장
16 Russo A, Franchina T, Ricciardi G, Battaglia A, Picciotto M, Adamo V. Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: new insights and future perspectives in this complex clinical scenario. Int J Mol Sci. 2019;20:1431. 미소장
17 Bauml JM, Viteri S, Minchom A, Bazhenova L, Ou S, Schaffer M, et al. FP07.12 Uderdiagnosis of EGFR exon 20 insertion mutation variants: estimates from NGS-based Real-World Datasets. J Thorac Oncol. 2021;16(3 Suppl):S208-9. 미소장
18 Shah MP, Aredo JV, Padda SK, Ramchandran KJ, Wakelee HA, Das MS, et al. EGFR exon 20 insertion NSCLC and response to platinum-based chemotherapy. Clin Lung Cancer. 2022;23:e148-53. 미소장
19 Choudhury NJ, Schoenfeld AJ, Flynn J, Falcon CJ, Rizvi H, Rudin CM, et al. Response to standard therapies and comprehensive genomic analysis for patients with lung adenocarcinoma with EGFR exon 20 insertions. Clin Cancer Res. 2021; 27:2920-7. 미소장
20 Gadgeel S, Rodriguez-Abreu D, Speranza G, Esteban E, Felip E, Domine M, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2020;38:1505-17. 미소장
21 Kang EJ, Min KH, Hur GY, Lee SY, Shim JJ, Kang KH, et al. Comparison of the efficacy between pemetrexed plus platinum and non-pemetrexed plus platinum as first-line treatment in patients with wild-type epidermal growth factor receptor nonsquamous non-small cell lung cancer: a retrospective analysis. Chemotherapy. 2016;61:41-50. 미소장
22 Metro G, Baglivo S, Bellezza G, Mandarano M, Gili A, Marchetti G, et al. Sensitivity to immune checkpoint blockade in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations. Genes (Basel). 2021;12:679. 미소장
23 Chen K, Pan G, Cheng G, Zhang F, Xu Y, Huang Z, et al. Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions. Thorac Cancer. 2021;12:218-26. 미소장
24 Naidoo J, Sima CS, Rodriguez K, Busby N, Nafa K, Ladanyi M, et al. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib. Cancer. 2015;121:3212-20. 미소장
25 Janssen announces U.S. FDA breakthrough therapy designation granted for JNJ-6372 for the treatment of non-small cell lung cancer [Internet]. New Brunswick, NJ: Johnson & Johnson; c2020 [cited 2023 May 4]. Available from: https://www.jnj.com/janssen-announces-u-s-fda-breakthrough-therapy-designation-granted-for-jnj-6372-for-the-treatment-of-non-small-cell-lung-cancer. 미소장
26 Takeda announces U.S. FDA breakthrough therapy designation for mobocertinib (TAK-788) for the treatment of NSCLC patients with EGFR exon 20 insertion mutations [Internet]. Osaka: Takeda; c2020 [cited 2023 May 4]. Available from: https://www.takeda.com/newsroom/newsreleases/2020/takeda-announces-u.s.-fda-breakthrough-therapy-designation-for-mobocertinib-tak-788-for-the-treatment-of-nsclc-patients-with-egfr-exon-20-insertion-mutations. 미소장
27 Agrawal T, Artis E, Xie J, Bhattacharya A, Haddish-Berhane N, Gopen T, et al. P76.74 PAPILLON: Randomized phase 3 study of amivantamab plus chemotherapy vs chemotherapy alone in EGFR exon20ins NSCLC. J Thorac Oncol. 2021;16(3 Suppl):S621. 미소장
28 Sava J. FDA and Takeda to withdraw mobocertinib for EGFR Exon20+ NSCLC [Internet]. Cranbury, NJ: Targeted Oncology; c2023 [cited 2023 Dec 27]. Available from: https://www.targetedonc.com/view/fda-and-takeda-to-withdraw-mobocertinib-for-egfr-exon20-nsclc. 미소장
29 Baek MY, Ahn HK, Park KR, Park HS, Kang SM, Park I, et al. Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer. Korean J Intern Med. 2018;33:168-75. 미소장
30 Riely GJ, Neal JW, Camidge DR, Spira AI, Piotrowska Z, Costa DB, et al. Activity and safety of mobocertinib (TAK-788) in previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations from a phase I/II trial. Cancer Discov. 2021;11:1688-99. 미소장
31 Vyse S, Huang PH. Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer. Expert Rev Anticancer Ther. 2022;22:3-16. 미소장
32 Vyse S, Huang PH. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther. 2019;4:5. 미소장

추천서가 (다양한 추천 자료를 만나보세요)

권호기사보기

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 기사목차